Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nolatrexed. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nolatrexed SCHEMBL1649851 | 0.99 | TYMS (0.65) | TYMSDHFR | |
| Nolatrexed SCHEMBL710461 | 0.80 | TYMS (1.00) | TYMSDHFR | |
| Nolatrexed SCHEMBL27935384 | 0.79 | TYMS (0.97) | TYMSDHFR | |
| Nolatrexed SCHEMBL29420099 | 0.79 | TYMS (0.97) | TYMSDHFR | |
| Nolatrexed SCHEMBL316632 | 0.79 | TYMS (0.97) | TYMSDHFR | |
| SCHEMBL7826662 | 0.71 | TYMS (1.00) | TYMS | |
| SCHEMBL16807869 | 0.68 | TYMS (0.61) | TYMSDHFR | |
| SCHEMBL710460 | 0.64 | TYMS (0.53) | TYMSDHFR | |
| Hydrochloric Acid SCHEMBL4539745 | 0.63 | TYMS (0.52) | TYMSDHFR | |
| SCHEMBL28069299 | 0.62 | TYMS (0.45) | TYMSDHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10016 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | claimed |
| US-20260022117-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS INC (US) | 2026-01-22 | — | — | US | claimed |
| EP-4680203-A1 | COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS | Prolevi Bio AB (SE) | 2026-01-21 | — | — | EP | claimed |
| US-12485178-B2 | Bifunctional small molecules to target the selective degradation of circulating proteins | YALE UNIVERSITY (US) | 2025-12-02 | — | — | US | claimed |
| US-20250332274-A1 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | UNIV YALE (US) | 2025-10-30 | — | — | US | claimed |
| US-20250319123-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2025-10-16 | — | — | US | claimed |
| US-20250319188-A1 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2025-10-16 | — | — | US | claimed |
| US-12364766-B2 | Bifunctional small molecules to target the selective degradation of circulating proteins | YALE UNIVERSITY (US) | 2025-07-22 | — | — | US | claimed |
| US-12364682-B2 | Use of tegaserod in preparation of anti-tumor drug | QINGDAO HAIJI BIOMEDICINE CO., LTD. (CN) | 2025-07-22 | — | — | US | claimed |
| EP-1597393-A2 | METHODS OF DETERMINING A CHEMOTHERAPEUTIC REGIMEN BASED ON LOSS OF HETEROZYGOSITY AT THE THYMIDYLATE SYNTHASE LOCUS | Response Genetics, Inc. (US) | 2005-11-23 | — | — | EP | claimed |
| US-20050118613-A1 | Methods and kits for predicting the likelihood of successful treatment of cancer | ONCOMETHYLOME SCIENCES S.A. | 2005-06-02 | — | — | US | claimed |
| WO-2005012569-A1 | METHODS AND KITS FOR PREDICTING THE LIKELIHOOD OF SUCCESSFUL TREATMENT OF CANCER | THE UNIVERSITY OF WESTERN AUSTRALIA (AU) | 2005-02-10 | — | — | WO | claimed |
| EP-1501514-A2 | PROTEIN KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2005-02-02 | — | — | EP | claimed |
| US-20040235829-A1 | Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC | 2004-11-25 | — | — | US | claimed |
| WO-2004078747-A1 | NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-09-16 | — | — | WO | claimed |
| WO-2004075833-A2 | METHODS OF DETERMINING A CHEMOTHERAPEUTIC REGIMEN BASED ON LOSS OF HETEROZYGOSITY AT THE THYMIDYLATE SYNTHASE LOCUS | RESPONSE GENETICS, INC. (US) | 2004-09-10 | — | — | WO | claimed |
| US-20040170983-A1 | Methods of determining a chemotherapuetic regimin based on loss of heterozygosity at the thymidylate synthase locus | RESPONSE GENETICS, INC. | 2004-09-02 | — | — | US | claimed |
| WO-2003093297-A2 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2003-11-13 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |